This isn’t a raise.
It’s a mandate.
A focused Seed round to accelerate the software layer of Indian medicine and commerce — two operating companies, one holding structure, dual-stream revenue architecture, twenty-four month runway.
The terms, on one page.
A single closing. Founder-friendly instrument. Priced for partners who intend to stay on the cap table for a decade.
Allocation of the ₹2 Cr raise.
Sequenced to defend the physician-first moat, deepen operating software, and extend runway to institutional Series A.
A dual-stream architecture.
Marketplace GMV commissions from Aethex and Zyphix compound with retention. India’s 1.2 million doctors and dense urban consumer base form a chronic-purchase economy with high repeat frequency.
High-margin operating software layered on top creates defensible moats and strong gross retention.
Together, the two streams create a compounding, capital-efficient group that improves with every physician and kirana onboarded.
Numbers, verified.
A ledger of what has actually shipped — not projections.
- Verified physicians on Aethex40,000+
- Active monthly subscribers12,000+
- Partner kiranas on Zyphix200+
- Pan-India delivery SLA (Aethex)2 days
- Quick-commerce median (Zyphix)30 min
- Regulatory postureNMC · CDSCO · DPDP
The parent groups we study.
The world’s most durable healthcare businesses are diversified operating groups. Clavix is architected the same way — starting India-first.
Source · Public filings, FY23–FY24 · Illustrative benchmarks only.